Quarterly siRNA Wins Phase 3 but Payer and Durability Risks Cloud Uptake
Regulatory Approvals

Quarterly siRNA Wins Phase 3 but Payer and Durability Risks Cloud Uptake

Published : 20 Nov 2026

At a Glance
Indicationgeneralized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive
Drugcemdisiran
Mechanism of ActionC5-directed siRNA
CompanyRegeneron Pharmaceuticals, Inc.
Trial PhasePhase 3
Trial AcronymNIMBLE
CategoryRegulatory Milestone
Sub CategoryApproval Granted
Therapeutic AreaNeuroscience
Approval DateNovember 18, 2026
Regulatory BodyU.S. Food and Drug Administration (FDA)
Dosing FrequencyFour times a year
Administration RouteSubcutaneous
Patient SubpopulationAdults, anti-acetylcholine receptor (AChR) antibody-positive
Primary EndpointMG-ADL total score change from baseline to week 24
Key Secondary EndpointQMG total score change from baseline to week 24
Common Adverse ReactionsInjection site reactions, viral infections, urinary tract infections
Safety InformationBoxed Warning for serious meningococcal infections, Livsayis Risk Evaluation and Mitigation Strategy (REMS)
Regulatory Status EUUnder review, decision anticipated H2 2027

FDA Approves Regeneron's Livsayis for Generalized Myasthenia Gravis

Regeneron Pharmaceuticals announced that the U.S. FDA has approved Livsayis (cemdisiran) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive. Livsayis is the first and only approved siRNA therapy for gMG and the only FDA-approved gMG treatment administered subcutaneously four times a year. The approval is based on results from the Phase 3 NIMBLE trial, which demonstrated rapid, deep, and sustained disease control, maintained throughout three-month dosing intervals. Livsayis showed significant improvements in MG-ADL and QMG total scores compared to placebo at 24 weeks, with clinically meaningful benefits observed as early as two weeks.

  • Livsayis demonstrated significant efficacy in the Phase 3 NIMBLE trial, showing a 4.5-point improvement on the Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score at 24 weeks, compared to a 2.2-point improvement with placebo (placebo-adjusted improvement of 2.3 points, p=0.0005). A greater proportion of Livsayis patients (76.6%) achieved at least a 3-point MG-ADL improvement versus placebo (44.1%, p<0.001).
  • The drug also achieved a 4.2-point improvement in Quantitative Myasthenia Gravis (QMG) total score at 24 weeks, compared to a 1.5-point improvement with placebo (placebo-adjusted improvement of 2.8 points, p=0.0015). Clinically meaningful benefits in MG-ADL were observed as early as two weeks, deepening over time and demonstrating sustained disease control through 24 weeks without waning efficacy.
  • Livsayis is a novel, complement component factor 5 (C5)-directed small interfering RNA (siRNA) therapeutic, functioning by reducing circulating C5 protein levels to limit terminal complement activation, a key driver of gMG. This mechanism makes it the first and only approved siRNA therapy for gMG and the only FDA-approved gMG treatment administered subcutaneously four times a year, significantly reducing treatment burden.

Addressing Unmet Needs in Generalized Myasthenia Gravis Treatment

Despite established therapies being effective in most patients with generalized myasthenia gravis, some patients do not respond or they experience intolerable adverse events, highlighting the need for better tolerated, targeted therapies for treatment-refractory disease. Long-term reliance on corticosteroids and conventional immunosuppressants carries substantial toxicity while still leaving a refractory subgroup with limited evidence-based options.

  • Treatment refractoriness persists in a meaningful subgroup: approximately 10-15% of patients with generalized AChR antibody-positive MG develop refractoriness to standard immunosuppressive therapies, with approximately 20% of patients with MG described as refractory to conventional immunosuppressive therapy.

  • Corticosteroid toxicity limits long-term use: long term steroid use carries substantial risks of severe adverse side effects, including weight gain of about 30 kg, steroid myopathy, cushingoid facies with bilateral exophthalmos, and increased annualized risk of new-onset diabetes (hazard ratios 1.32-1.76), infections (1.19-1.25), osteoporosis (1.33-1.69), cardiovascular disease (1.19-1.31), glaucoma (hazard ratio 1.81 at high dose) and depression, plus higher risk of major osteoporotic fracture with high dose glucocorticoid use (>7.5 mg/day).

  • Conventional immunosuppressants have delayed and difficult-to-prove benefit: non-steroidal immunosuppressive drugs have a delayed-onset effect and evidence of their efficacy appears to be difficult to obtain, compounded by a fluctuating disease course involving weakness that may be difficult to assess quantitively.

  • Acute rescue therapies fail in a proportion of crises: while plasma exchange (PLEX) and intravenous immunoglobulins (IVIG) are standard first-line therapies for myasthenic crisis, approximately 30% of patients may show suboptimal response.

  • Novel targeted agents bring monitoring and access constraints: these medications require vaccination and close monitoring for infections and hypersensitivity reactions, though challenges in cost and access remain, and patients with thymomatous MG exhibited a poorer response to efgartigimod and required two infusion cycles.

Unpacking Livsayis's C5-Directed siRNA Efficacy in gMG

The Phase 3 RAISE study (NCT04115293; N = 174) evaluated daily, self-administered, subcutaneous zilucoplan 0.3 mg/kg versus placebo for 12 weeks in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Zilucoplan is described as a macrocyclic peptide complement component 5 inhibitor. Mean (standard error) change from baseline to Week 12 in Myasthenia Gravis Activities of Daily Living score was -4.22 (0.71) with zilucoplan versus -2.61 (0.50) with placebo in the subgroup without prior immunoglobulin/PLEX, and -4.93 (0.54) versus -2.94 (0.50) in the subgroup with prior immunoglobulin/PLEX. Zilucoplan was well tolerated with a similar safety profile in both subgroups.

The Phase 3 ADAPT trial (NCT03669588) evaluated efgartigimod 10 mg/kg versus placebo administered as four once-weekly infusions per cycle for 26 weeks in acetylcholine receptor antibody-positive participants. In total, 129 AChR-Ab+ participants were included (efgartigimod, n = 65; placebo, n = 64). Across all subgroups, higher MG-ADL and QMG responder rates were observed in participants treated with efgartigimod versus placebo during cycles 1 and 2. Rates of treatment-emergent adverse events were similar between participants treated with efgartigimod and placebo, regardless of concomitant gMG treatment type.

In real-world settings, the ZILU25 multicenter observational study evaluated daily subcutaneous self-administered zilucoplan in AChR-positive generalized myasthenia gravis, with 54 patients (37 females, aged 57.3) receiving zilucoplan with a mean follow-up of 26.4 weeks. A clinical meaningful and significant reduction of MG-ADL, QMG, MGC and MG-QOL-15 scores from W4 to W12 and sustained at W24 was observed, with MG-ADL responder rate of 75.6 % at W12 and 82.9 % at W24, minimal symptoms expression in 55.6 % of patients at W48, and mean reduction of the daily prednisone dose of 8.3 mg at W24. Zilucoplan was well-tolerated. In an Italian multicenter retrospective study of ravulizumab, a monoclonal antibody targeting C5, in 24 anti-AChR positive generalized myasthenia gravis patients with median follow-up duration of 26 weeks (range 10-74, IQR 26-42), MG-ADL and QMG scores showed a significant decrease with respect to baseline (p < 0.001), minimal symptom expression was achieved by 37.5% patients at the last available follow-up, and tapering of prednisone daily dosage was possible in 76% of patients, while three patients discontinued treatment, one patient experienced a myasthenic exacerbation and needed rescue therapy, infectious adverse events were reported in 5/24 patients, and a Stevens-Johnson syndrome in one patient.

Understanding Livsayis's Safety Profile and REMS Program

Cemdisiran has been evaluated for safety and tolerability across IgA nephropathy, paroxysmal nocturnal hemoglobinuria (PNH), healthy subjects, and generalised myasthenia gravis. Across studies, cemdisiran was generally well tolerated with most adverse events mild or moderate and transient, and no new safety signals limiting further evaluation as monotherapy or in combination with C5 antibody therapy.

  • IgA nephropathy phase 2 trial: Over 36 weeks, most adverse events were mild or moderate and transient; the most common adverse event after cemdisiran treatment was injection-site reaction (41%). Treatment with cemdisiran 600 mg every 4 weeks was described as well tolerated.

  • Phase 1/2 study in healthy adults and PNH: Cemdisiran was generally well tolerated. Overall, 75%, 89%, and 100% of subjects in Parts A, B, and C, respectively, experienced ≥1 non-serious adverse event (AE). Most events were Grade 1 or 2 in severity and the most common AEs included nasopharyngitis and headache.

  • NIMBLE phase 3 trial in generalised myasthenia gravis: The proportion of participants with at least one adverse event during the 24-week double-blind treatment period was 54 (69%) of 78 in the cemdisiran group, 65 (81%) of 80 in the combination group, 40 (82%) of 49 in the pozelimab group, and 54 (77%) of 70 in the placebo group. The most common adverse event in the cemdisiran group was upper respiratory tract infection (nine [12%] of 78 patients), which occurred at a similar incidence in the placebo group (eight [11%] of 70). No serious or meningococcal infections occurred in the cemdisiran group. Adverse events leading to treatment discontinuation occurred in two participants (3%) in the placebo group and one participant (2%) in the pozelimab group. No deaths occurred during the double-blind treatment period. Two deaths occurred after the double-blind treatment period, one of which was assessed as treatment-related by the investigator but not treatment-related by the sponsor.

  • Phase 2 PNH combination trial of pozelimab and cemdisiran: While most patients (66.7%) experienced treatment-emergent adverse events, the majority of these events were mild to moderate in severity. No meningococcal infections, thrombotic events, or deaths were reported. Combination treatment was described as generally well tolerated.

  • Pharmacokinetic and pharmacodynamic study in healthy subjects and PNH: One of 48 subjects tested transiently positive for antidrug antibody with low titer, with no impact on PK or PD. Cemdisiran was reported to have low immunogenicity and acceptable safety profiles enabling low, infrequent SC dosing.

Frequently Asked Questions

What is the mechanism of action of cemdisiran in generalized myasthenia gravis?
Cemdisiran is an investigational RNA interference (RNAi) therapeutic designed to inhibit the production of complement component 5 (C5). By targeting C5, cemdisiran aims to prevent the formation of the membrane attack complex (MAC), a key effector of complement-mediated damage. This mechanism is intended to reduce the autoimmune attack on the neuromuscular junction in gMG.
Which patient population is cemdisiran being developed for in generalized myasthenia gravis?
Cemdisiran is specifically under investigation for the treatment of adult patients with generalized myasthenia gravis (gMG). Its development focuses on individuals who are positive for anti-acetylcholine receptor (AChR) antibodies. This patient subgroup represents a significant portion of gMG cases where complement activation plays a critical role.
How does complement inhibition impact the pathophysiology of anti-AChR positive gMG?
In anti-AChR positive gMG, autoantibodies bind to acetylcholine receptors at the neuromuscular junction, triggering the classical complement pathway. Inhibition of complement, particularly at the C5 level, prevents the downstream formation of the membrane attack complex (MAC). This action mitigates the destruction of the postsynaptic membrane and reduces inflammation, thereby preserving neuromuscular transmission.
What are the potential advantages of an RNAi therapeutic approach for gMG?
RNAi therapeutics offer a highly specific method to silence gene expression, allowing for targeted inhibition of disease-driving proteins like C5. This approach can lead to a sustained reduction in the target protein, potentially enabling less frequent dosing compared to other modalities. The precision of RNAi may also contribute to a favorable safety profile by minimizing off-target effects.

References

  1. [1] Akhtar M, Akhtar M et al.. Efficacy and safety of FcRn inhibitors in patients with Myasthenia gravis: An updated systematic review and meta‑analysis. Clinical neurology and neurosurgery. 2025 Jul. 40288289
  2. [2] Habib AA, Drużdż A et al.. Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension. Journal of neuromuscular diseases. 2025 Mar. 40034001
  3. [3] Siddiqi ZA, Qi CZ et al.. Cost-Effectiveness Analysis of Efgartigimod vs Chronic Immunoglobulin for the Treatment of Myasthenia Gravis in Canada. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. 2025 Oct 27. 41139802
  4. [4] Filippakopoulou E, Gavriilaki M et al.. Efficacy and safety of complement inhibitors and FcRn blockers in generalized AChR antibody-positive myasthenia gravis: a meta-analysis. Journal of neurology. 2026 Apr 2. 41925914
  5. [5] Devalaraja-Narashimha K, Huang C et al.. Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates. PloS one. 2022. 35709087
  6. [6] Parisi M, Molitierno N et al.. FcRn antagonist and C5 complement inhibitor as early rescue strategies in severe Myasthenia Gravis: a two-case report. Frontiers in immunology. 2026. 42404894
  7. [7] Versino F, Fattizzo B. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy. International journal of laboratory hematology. 2024 May. 38622956
  8. [8] Jiang L, Wei J et al.. Efgartigimod for generalized myasthenia gravis: a comprehensive review of clinical evidence and future perspectives. Frontiers in neurology. 2026. 42358938
  9. [9] Jang JH, Wong RSM et al.. Safety, Efficacy, and Patient-Reported Outcomes From a Phase 2 Randomized Trial of Pozelimab and Cemdisiran Combination in Patients With Paroxysmal Nocturnal Hemoglobinuria. EJHaem. 2025 Aug. 40708708
  10. [10] Grimm SL, Fierz FC et al.. The Spurious Palsy-Fluctuation of Ocular Myasthenia Gravis Symptoms Characterized by Orthoptics. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 2025 Dec 1. 40198267
  11. [11] Xu XQ. [Clinical efficacy of Yiqi Qushi Recipe in treating myasthenia gravis and observation of its immunomodulatory effects]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine. 2013 Feb. 23646470
  12. [12] Park HS, Kim K et al.. Risk of fracture in patients with myasthenia gravis: a nationwide cohort study in Korea. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2024 Jul 23. 38477782
  13. [13] Qi CZ, Lin Y et al.. Impact of corticosteroid use on comorbidities in patients with myasthenia gravis in the US National Veterans Affairs Health Network. Journal of the neurological sciences. 2026 Feb 15. 41534441
  14. [14] Rossini E, Di Stefano V et al.. Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience. Journal of neurology. 2025 May 14. 40366475
  15. [15] Filippone EJ, Gulati R et al.. The road ahead: emerging therapies for primary IgA nephropathy. Frontiers in nephrology. 2025. 39968279
  16. [16] Yang Q, Yu S et al.. Perioperative Administration of Efgartigimod in myasthenia gravis patients with Thymoma: A six-case series. Journal of neuroimmunology. 2026 Nov. 42462363
  17. [17] Ji Y, Zhou S et al.. Clinical heterogeneity, treatment patterns, and outcomes of advanced-age-onset myasthenia gravis in China: a retrospective cohort study. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2025 Nov. 40865296
  18. [18] Silvestri NJ. Individualized Dosing of Efgartigimod in Patients With Generalized Myasthenia Gravis: Clinical Experience at a Single Center. Muscle & nerve. 2025 Mar. 39744896
  19. [19] Sharma I, Panta R. Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine. Cureus. 2025 Dec. 41573494

Contact Us

📍

Address

350 Springfield Avenue,
Suite #200 Summit, NJ 07901

✉️

For General Inquiry

info@pienomial.com

Related Posts